LEVO-DROMORAN (levorphanol tartrate) · VALEANT PHARM INTL
LEVO-DROMORAN is FDA-approved to treat 1 condition (same as LEVORPHANOL TARTRATE).
Details
- Status
- Discontinued
- First Approved
- 1953-01-08
- Routes
- INJECTION, ORAL
- Dosage Forms
- INJECTABLE, TABLET
LEVO-DROMORAN Approval History
What LEVO-DROMORAN Treats
1 indicationsLEVO-DROMORAN is approved for 1 conditions since its original approval in 1953. These indications span multiple therapeutic areas including oncology, immunology, and more.
Same approved indications as LEVORPHANOL TARTRATE (same active ingredient).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LEVO-DROMORAN FDA Label Details
Indications & Usage
LEVO-DROMORAN is FDA-approved to treat 1 condition — same approved indications as LEVORPHANOL TARTRATE.
Track LEVO-DROMORAN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.